About Delcath
Delcath is a publicly listed company based in New York (United States) founded in 1987. Delcath Systems, Inc. is focused on liver cancer treatments. It operates on a HealthTech model. The company has 96 employees. Delcath offers products and services including HEPZATO KIT™ and CHEMOSAT®. Its focus areas include Oncology and Interventional Oncology. Its legal entity is Delcath Systems, Inc. Its competitors include TriSalus Life Sciences, Cooler Heads and Embolx; 3 of its 3 listed competitors have raised funding.
Company details
Delcath Systems, Inc. is recognized as an interventional oncology company dedicated to the treatment of primary and metastatic liver cancers. Solutions are developed to provide targeted, safe, and effective minimally-invasive treatments for patients. The impact of liver cancer, affecting 1.2 million people globally each year, is addressed through innovative products like HEPZATO KIT for metastatic Uveal Melanoma in the United States and CHEMOSAT Hepatic Delivery System in Europe. Commitment is shown in revolutionizing care for liver cancer patients by exploring beyond conventional treatment options.
- Headquarters New York, United States
- Employees 96
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website delcath.com
- Social LinkedIn YouTube
- Legal Name Delcath Systems, Inc.
- Annual Revenue$85.23 M (USD)129.08as on Dec 31, 2025
- Net Profit$2.7 M (USD)as on Dec 31, 2025
- EBITDA$1.01 M (USD)as on Dec 31, 2025
- Latest Funding Round$16.3M (USD), Post-IPO
Dec 2024
- InvestorsCanaccord Genuity Group
& 8 more
- Employee Count96
Products & Services of Delcath
Delcath offers a comprehensive portfolio of products and services, including HEPZATO KIT™ and CHEMOSAT®.
Treatment for metastatic Uveal Melanoma in adults provided.
Hepatic delivery system for Melphalan perfusion offered.
Apps and channels of Delcath
its YouTube channel Delcath has 22 subscribers and 6 videos.
Videos from Delcath
The most watched videos on Delcath's YouTube channel, Delcath (22 subscribers). Click a video to play it here.
More on Delcath.
Funding Insights of Delcath
- Total Rounds 21
- Last Round Post-IPO — $16.3M
- First Round $267,500
(Apr 2002)
- Investors Count 9
Latest 10 of 21 funding rounds of Delcath with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $16.3M | Post-IPO | – | – | – |
| Mar 2024 | $7M | Post-IPO | – | – | – |
| Mar 2023 | $35M | Post-IPO | – | – | |
| Dec 2022 | $6.2M | Post-IPO | – | – | – |
| Jul 2022 | $5M | Post-IPO | – | – | – |
| Aug 2019 | $9.51M | Post-IPO | – | – | |
| Jul 2019 | $20M | Post-IPO | – | – | – |
| Oct 2018 | $100M | Post-IPO | – | – | – |
| Jul 2018 | $1.6M | Post-IPO | – | – | – |
| Sep 2017 | $500,000 | Post-IPO | – | – | – |
9 investors in total: 9 institutional.
Investors in Delcath
Delcath has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Canaccord Genuity Group, Jefferies and Vivo Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Provides investment management for life sciences and biotech funds to investors worldwide. | 2006 | rosalindcap.com | Toronto, Canada | |
Life-science investment management firm providing advisory and capital services in biotechnology and healthcare. | 2006 | stonepinecap.com | Bend, United States | |
| gcaaltium.com | ||||
Merger and acquisitions advisory firm | 1950 | canaccordgenuity.com | Toronto, Canada | |
Merger and acquisitions advisory services are provided across multiple sectors. | 1962 | jefferies.com | New York, United States |
Investor details for Delcath
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Delcath
36 people are tracked at Delcath (17 in leadership, 4 in board & advisors, 15 in team); the tracked headcount is 96.
| Name | Role | Group |
|---|---|---|
Waleed Shalaby | Vice President Medical Affairs | Leadership |
Kevin Muir | Vp, General Manager Interventional Oncology | Leadership |
Sultan Mahmood BSc MBA | General Manager EMEA Interventional Oncology | Leadership |
Ray Treacy | Director Quality Assurance, EMEA | Leadership |
Sandra Brooks Pennell | Chief Financial Officer | Leadership |
Suzy Palmer | Director GCP QA | Leadership |
Martha Rook | Chief Operating Officer | Leadership |
Steven Salamon | Director | Leadership |
Chuck Frigon | VP of Operations | Leadership |
Gerard Michel | Chief Executive Officer | Leadership |
Carol Crooke, MS, RN, OCN | Assoc. Vice President Clinical Operations At Delcath Systems, Inc. | Leadership |
David Hoffman | General Counsel And Chief Compliance Officer | Leadership |
Helen Shapiro | Senior Director Clinical Operations | Leadership |
Zac MacLean | Vice President Of Sales | Leadership |
Kent Vickerman | Sr Director Quality Assurance | Leadership |
Darwin Keith-Lucas | Senior Director, Program Management | Leadership |
Vojo Vukovic | Chief Medical Officer | Leadership |
Roger G. Stoll | Executive Chairman | Board & advisors |
Gil Aharon | Director | Board & advisors |
Elizabeth Czerepak | Director | Board & advisors |
16 more people are available in the full profile.
Complete people profiles for Delcath
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Delcath
Delcath is a publicly listed company on the NASDAQ with ticker symbol DCTH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 May 2002
- Listed onNASDAQ: DCTH
- Listed entityDelcath Systems, Inc.
- Exchange sectorHealth technology
- ISINUS24661P8077
- Share price$15.32 (-2.23% on the day) · 2026-10-13
- Market capitalisation$531.6M
- Price to earnings2,511.5
- EPS (diluted, trailing year)$0.01
- Volume (last session)251,355
Financials of Delcath
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $85.2M | $2.7M | $1.0M |
| 2024 | $37.2M | -$26.4M | -$12.2M |
| 2023 | $2.1M | -$47.7M | -$38.0M |
| 2022 | $2.7M | -$36.5M | -$33.3M |
| 2021 | $3.6M | -$25.6M | -$24.1M |
Detailed financial statements for Delcath
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Delcath
4 dated milestones of Delcath across 37 years, from founding to its latest funding, stage changes and deals.
- Founded Delcath is founded.
- Funding First funding round of $268K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $16.3M.
Competitors of Delcath
Delcath has 3 listed competitors in our database, 3 of them funded. They include TriSalus Life Sciences, Cooler Heads and Embolx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| trisaluslifesci.com | 2009 | Westminster, United States | $83.37M | 100 | Developer of drug delivery devices to treat cancers | |
| coolerheads.com | 1998 | San Diego, United States | $23.11M | Developer of cold cap system to prevent chemotherapy side effects | ||
| embolx.com | 2013 | Sunnyvale, United States | $500,000 | Catheter-based system for localized cancer therapy is being developed. |
Detailed competitors of Delcath
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Delcath
The website of Delcath (delcath.com) receives about 7.5K visits a month.
- Monthly visits7.5K
▼ 24.1% vs previous month
Websites whose visitors overlap most with Delcath. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| formds.com | 100% | 20.7K | #843,175 | View details | |
| twst.com | 100% | 15.3K | #1,450,074 | View details | |
tickerreport.com | tickerreport.com | 80% | #1,591,824 | – |
Top companies in Oncology
3 companies that operate in the same segment as Delcath (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Delcath
Complete news archive for Delcath
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Delcath
Delcath was founded in 1987 and raised its 1st funding round 15 years after it was founded.
Delcath is headquartered in New York, United States. It is registered at New York, New York, United States.
Delcath has 96 employees.
Annual revenue of Delcath is $85.23M as on Dec 31, 2025.
Delcath Systems, Inc. is recognized as an interventional oncology company dedicated to the treatment of primary and metastatic liver cancers. Solutions are developed to provide targeted, safe, and effective minimally-invasive treatments for patients. The impact of liver cancer, affecting 1.2 million people globally each year, is addressed through innovative products like HEPZATO KIT for metastatic Uveal Melanoma in the United States and CHEMOSAT Hepatic Delivery System in Europe. Commitment is shown in revolutionizing care for liver cancer patients by exploring beyond conventional treatment options.
Delcath's top competitors include TriSalus Life Sciences, Cooler Heads and Embolx.
Delcath offers HEPZATO KIT™ and CHEMOSAT®.
Yes, Delcath is publicly traded on NASDAQ under the ticker symbol DCTH.
Delcath has 9 investors. Key investors include Canaccord Genuity Group, Jefferies, Vivo Capital, Logos Capital, and BVF Partners.
Delcath operates through Delcath Systems, Inc..